EFPIA response to the EMA Regulatory Science Strategy to 2025

1 juillet 2019

BlueRegWatch

EFPIA welcomes the opportunity to comment on the Agency’s Regulatory Science Strategy (RSS) to 2025. EFPIA has identified a series of priorities that the innovative biopharmaceutical industry believes will have the most substantive benefit for European citizens, as well for the global community, by ensuring that Europe remains at the frontier of innovation in healthcare.

BlueRegWatch

Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :

Découvrez notre dernier livre blanc

En savoir plus